Correlation Between Sutro Biopharma and Inhibrx

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sutro Biopharma and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sutro Biopharma and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sutro Biopharma and Inhibrx, you can compare the effects of market volatilities on Sutro Biopharma and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sutro Biopharma with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sutro Biopharma and Inhibrx.

Diversification Opportunities for Sutro Biopharma and Inhibrx

0.57
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Sutro and Inhibrx is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Sutro Biopharma and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Sutro Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sutro Biopharma are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Sutro Biopharma i.e., Sutro Biopharma and Inhibrx go up and down completely randomly.

Pair Corralation between Sutro Biopharma and Inhibrx

Given the investment horizon of 90 days Sutro Biopharma is expected to under-perform the Inhibrx. In addition to that, Sutro Biopharma is 1.99 times more volatile than Inhibrx. It trades about -0.29 of its total potential returns per unit of risk. Inhibrx is currently generating about 0.02 per unit of volatility. If you would invest  1,493  in Inhibrx on October 10, 2024 and sell it today you would earn a total of  5.00  from holding Inhibrx or generate 0.33% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Sutro Biopharma  vs.  Inhibrx

 Performance 
       Timeline  
Sutro Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sutro Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Sutro Biopharma and Inhibrx Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sutro Biopharma and Inhibrx

The main advantage of trading using opposite Sutro Biopharma and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sutro Biopharma position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.
The idea behind Sutro Biopharma and Inhibrx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Valuation
Check real value of public entities based on technical and fundamental data